InflaRx N.V. Business Summary

InflaRx N.V. is a clinical-stage biopharmaceutical company that generates revenue primarily through the commercial sale of GOHIBIC (vilobelimab) under U.S. FDA Emergency Use Authorization (EUA) and through strategic "Other Income" streams, including government research allowances and milestone-based licensing. The company’s business segments are centered on its proprietary anti-C5a technology platform, focusing on the development of first-in-class monoclonal antibodies and small-molecule inhibitors like Izicopan (INF904) for life-threatening inflammatory diseases. InflaRx operates within a highly specialized niche of the complement system market, competing directly with industry leaders such as Alexion Pharmaceuticals (AstraZeneca), Apellis Pharmaceuticals, and ChemoCentryx (Amgen). Relative to these peers, InflaRx distinguishes itself by specifically targeting the terminal C5a/C5aR signaling pathway to prevent tissue damage while preserving the immune system's upstream defense mechanisms. The company was co-founded by CEO Prof. Niels C. Riedemann and CSO Prof. Renfeng Guo, both of whom possess deep academic and clinical pedigrees in complement-mediated inflammation research. The leadership team is further bolstered by CFO Dr. Thomas Taapken, who brings extensive experience in public biotech finance from roles at Medigene and Epigenomics, and CMO Dr. Camilla Chong, who oversees global clinical development. The company is governed by a board led by Chairman Nicolas Fulpius and includes industry veterans like Tony Gibney and Richard Brudnick. Notable institutional backing includes significant positions from Bank of America, Sofinnova Investments, and 683 Capital Management, reflecting strong investor confidence in the company’s long-term pipeline potential despite its current pre-profit status.